Today, Ocugen announced that Health Canada provided a “No Objection Letter” to initiate the OCU400 Phase 3 liMeliGhT clinical trial. Clinical sites in Canada may expedite recruitment and open doors for broader commercialization with the U.S. and Europe. bit.ly/3AE1kUl